Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Wing‐Kai Chan"'
Autor:
David Wang, Natalie Hughes-Medlicott, Lilian Klingler, Yi Wang, Noelyn Hung, Stephen Duffull, Tak Hung, Paul Glue, Albert Qin, Rudolf Kwan, Wing-Kai Chan, Christopher Jackson
Publikováno v:
Pharmaceutics, Vol 16, Iss 5, p 602 (2024)
Introduction: Docetaxel, a taxane used in the treatment of solid tumours, exerts pharmacological activity when in its unbound form. We report a sensitive assay to quantify unbound docetaxel after oral administration of docetaxel plus encequidar (oDox
Externí odkaz:
https://doaj.org/article/ae358746e1214a738575fdd1bdff5015
Autor:
Ming-Shen Dai, Ta-Chung Chao, Chang-Fang Chiu, Yen-Shen Lu, Her-Shyong Shiah, Christopher G. C. A. Jackson, Noelyn Hung, Jianguo Zhi, David L. Cutler, Rudolf Kwan, Douglas Kramer, Wing-Kai Chan, Albert Qin, Kuan-Chiao Tseng, Cheung Tak Hung, Tsu-Yi Chao
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Paclitaxel is widely used for the treatment of metastatic breast cancer (MBC). However, it has a low oral bioavailability due to gut extrusion caused by P-glycoprotein (P-gp). Oral paclitaxel (oPAC) may be more convenient, less resource-i
Externí odkaz:
https://doaj.org/article/c0df0803d9fb4cc49e7cf54109162455
Autor:
Jimmy He, Christopher G. C. A. Jackson, Sanjeev Deva, Tak Hung, Katriona Clarke, Eva Segelov, Tsu‐Yi Chao, Ming‐Shen Dai, Hsien‐Tang Yeh, Wen Wee Ma, Douglas Kramer, Wing‐Kai Chan, Rudolf Kwan, David Cutler, Jay Zhi
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 7, Pp 867-879 (2022)
Abstract Oraxol consists of an oral dosage form of the chemotherapeutic agent paclitaxel administered with a novel P‐glycoprotein inhibitor encequidar methanesulfonate monohydrate (formerly named HM30181A), which allows oral treatment of cancers th
Externí odkaz:
https://doaj.org/article/6f50ac2d7cfa49bfb26f56d0d6565aae
Autor:
Jin-Bon Hong, Po-Yuan Wu, Albert Qin, Yi-Wen Huang, Kuan-Chiao Tseng, Ching-Yu Lai, Wing-Kai Chan, Jane Fang, David L. Cutler, Tsen-Fang Tsai
Publikováno v:
Pharmaceutics, Vol 14, Iss 10, p 2159 (2022)
Plaque-type psoriasis is a common skin disorder. Tirbanibulin (KX01) is a new Src kinase inhibitor with potent antiproliferative activity against keratinocytes and has been approved for treatment of actinic keratosis. This Phase I study investigates
Externí odkaz:
https://doaj.org/article/3bad5e6818634c3fb39be705f2a26129
Autor:
Wen Wee Ma, Jenny J. Li, Nilofer S. Azad, Elaine T. Lam, Jennifer R. Diamond, Grace K. Dy, Mateusz Opyrchal, Jay Zhi, Douglas Kramer, Wing-Kai Chan, David Cutler, Rudolf Kwan, Alex A. Adjei, Antonio Jimeno
Publikováno v:
Cancer Chemotherapy and Pharmacology. 90:7-17
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b4ae99bafe70d07102f42b5929800257
https://doi.org/10.1007/s00280-022-04443-1
https://doi.org/10.1007/s00280-022-04443-1
Autor:
Pan-Chyr Yang, Wing-Kai Chan, Jin-Yuan Shih, Szu-Hua Pan, Shuenn-Chen Yang, Ming-Heng Wu, Yi-Chuan Chung, Yu-Chih Chao, Ang Yuan, Yi-Ying Wu, Yuh-Ling Chen, Tse-Ming Hong
Supplementary Data from Targeting Neuropilin 1 as an Antitumor Strategy in Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::291db9762755f1c2f76260008e88bd9f
https://doi.org/10.1158/1078-0432.22439587
https://doi.org/10.1158/1078-0432.22439587
Autor:
Pan-Chyr Yang, Wing-Kai Chan, Jin-Yuan Shih, Szu-Hua Pan, Shuenn-Chen Yang, Ming-Heng Wu, Yi-Chuan Chung, Yu-Chih Chao, Ang Yuan, Yi-Ying Wu, Yuh-Ling Chen, Tse-Ming Hong
Purpose: Neuropilin 1 (NRP1) is a mediator of lung branching and angiogenesis in embryonic development and angiogenesis in cancer. The role of NRP1 in cancer progression is not fully elucidated. We investigated the role of NRP1 in cancer invasion and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16e47c6f02e2684377178d759db70ffa
https://doi.org/10.1158/1078-0432.c.6517024.v1
https://doi.org/10.1158/1078-0432.c.6517024.v1
Autor:
Patrick M. Boland, Christos Fountzilas, Marwan Fakih, Mateusz Opyrchal, Jennifer R. Diamond, Bradley Corr, Wen Wee Ma, Michelle Redman, Wing-Kai Chan, Hui Wang, Doug Kramer, Rudolf Kwan, David Cutler, Jay Zhi, Antonio Jimeno
Publikováno v:
Cancer chemotherapy and pharmacology. 90(2)
Irinotecan is a commonly used chemotherapeutic in solid tumor malignancies. Oratecan is an investigational product comprised of encequidar methanesulfonate, a novel minimally absorbed P-glycoprotein pump inhibitor, and irinotecan. This study sought t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31b49acc47391fc7d89a6b5e2a902b88
https://pubmed.ncbi.nlm.nih.gov/35904620
https://pubmed.ncbi.nlm.nih.gov/35904620
Autor:
Vinod Ravi, Michael Wagner, Tom Wei-Wu Chen, Herbert H Loong, Robert Mennel, Cheuh-Chuan Yen, Glen Clack, David Cutler, Rudolf Kwan, Wing=Kai CHan
Publikováno v:
Cancer Research. 81:PS13-05
Background Cutaneous angiosarcomas are highly aggressive malignant tumors with poor prognosis. Currently there is no FDA-approved treatment. oPac+E is a combination of oral paclitaxel and a novel oral P-glycoprotein inhibitor, Encequidar. Materials a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd5b0129daabf9de5298ad3d4f01896c
https://doi.org/10.1158/1538-7445.sabcs20-ps13-05
https://doi.org/10.1158/1538-7445.sabcs20-ps13-05
Autor:
Eva Segelov, David M. Cutler, Tsu Yi Chao, Noelyn Hung, Katriona Clarke, Tak Hung, Blair McLaren, Sanjeev Deva, Ming-Shen Dai, Jay Zhi, Paula Barlow, Douglas Kramer, Jimmy He, Christopher Jackson, Wing-Kai Chan, Hsien-Tang Yeh, Rudolf Kwan, Hans Prenen
Publikováno v:
British journal of clinical pharmacology
Background and purpose: Paclitaxel is a widely used anti-neoplastic agent but has low oral bioavailability due to gut extrusion by P-glycoprotein (P-gp). Oral paclitaxel could be more convenient, less resource intensive, and more tolerable than intra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cc8a24fcafa45afc827258ef6f4b74c
https://doi.org/10.22541/au.160978542.20993766/v1
https://doi.org/10.22541/au.160978542.20993766/v1